Stock listing

CSE:LOBE Lobe Sciences Ltd Stock

Home listing (CSE) of Lobe Sciences Ltd

Follow Lobe Sciences Ltd into a list and get an email when it puts out news.

Share price · CSE:LOBE

$0.05 CAD 0.00 (0.0%)

Close on Nov 20, 2026

Past year +25.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.05 – $0.05 CADNov 20, 2026
Volume
26,000 sharesNov 20, 2026
Market cap
$17.95M CADAt the close on Nov 20, 2026 · price × 359.0M shares outstanding
52-week range
$0.03 – $0.18 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$4,618 CADMedian day 37,750 shares · 14 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Lobe Sciences Ltd logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
CSE:LOBE · Home$0.05 CAD0.00 (0.0%)26,000$0.05$0.05$0.05$0.05Close on Nov 20, 2026
OTC:LOBEF$0.036 USD-0.003 (-7.2%)43,274$0.033$0.036$0.032$0.039Close on Nov 20, 2026
Frankfurt:LOBE€0.025 EUR-0.005 (-15.5%)—€0.025€0.025€0.025€0.029Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · CSE:LOBE · CAD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.050.000.0%$0.05$0.05$0.0526,000
$0.050.000.0%$0.05$0.055$0.0531,000
$0.050.000.0%$0.05$0.05$0.055,000
$0.05+0.005+11.1%$0.055$0.055$0.0516,839
$0.0450.000.0%$0.045$0.05$0.04545,500
$0.045+0.005+12.5%$0.045$0.045$0.04510,166
$0.040.000.0%$0.04$0.04$0.0446,000
$0.040.000.0%$0.04$0.04$0.0375,303
$0.040.000.0%$0.04$0.04$0.0455,101
$0.04+0.005+14.3%$0.035$0.04$0.03187,000
$0.035-0.005-12.5%$0.04$0.04$0.03544,500
$0.040.000.0%$0.035$0.04$0.03556,861
$0.040.000.0%$0.04$0.04$0.0445,000
$0.04-0.005-11.1%$0.055$0.055$0.04146,500
$0.045+0.005+12.5%$0.045$0.055$0.04645,000
$0.04-0.015-27.3%$0.055$0.055$0.04323,818
$0.0550.000.0%$0.055$0.055$0.05514,334
$0.055+0.015+37.5%$0.045$0.055$0.04582,000
$0.040.000.0%$0.04$0.04$0.0487,095
$0.04+0.005+14.3%$0.035$0.04$0.035497,750
$0.035-0.015-30.0%$0.05$0.05$0.035993,068
$0.050.000.0%$0.05$0.05$0.0547,000
$0.050.000.0%$0.05$0.05$0.0533,000
$0.050.000.0%$0.05$0.05$0.058,000
$0.050.000.0%$0.05$0.05$0.050
$0.05+0.005+11.1%$0.045$0.05$0.04531,000
$0.045-0.005-10.0%$0.05$0.05$0.045140,000
$0.05-0.01-16.7%$0.06$0.06$0.0530,857
$0.06+0.01+20.0%$0.05$0.06$0.0542,500
$0.050.000.0%$0.05$0.06$0.045189,000
$0.050.000.0%$0.05$0.05$0.05233,800
$0.05-0.005-9.1%$0.055$0.055$0.05222,500
$0.0550.000.0%$0.055$0.055$0.055162,000
$0.0550.000.0%$0.055$0.055$0.055172,750
$0.0550.000.0%$0.065$0.065$0.05594,000
$0.055-0.02-26.7%$0.075$0.075$0.05575,600
$0.0750.000.0%$0.075$0.075$0.07511,500
$0.0750.000.0%$0.07$0.075$0.07397,000
$0.0750.000.0%$0.075$0.075$0.0750
$0.0750.000.0%$0.075$0.075$0.0750
$0.075+0.01+15.4%$0.06$0.075$0.0644,666
$0.0650.000.0%$0.065$0.065$0.0650
$0.065-0.01-13.3%$0.065$0.065$0.06515,000
$0.0750.000.0%$0.075$0.075$0.0750
$0.075+0.005+7.1%$0.07$0.075$0.0726,000
$0.070.000.0%$0.07$0.07$0.065165,000
$0.070.000.0%$0.08$0.08$0.07112,000
$0.07-0.01-12.5%$0.07$0.07$0.0754,166
$0.080.000.0%$0.08$0.08$0.080
$0.080.000.0%$0.08$0.08$0.080
$0.080.000.0%$0.08$0.08$0.080
$0.080.000.0%$0.08$0.08$0.080
$0.080.000.0%$0.08$0.08$0.080
$0.08-0.005-5.9%$0.085$0.085$0.0820,000
$0.0850.000.0%$0.085$0.085$0.0850
$0.085-0.005-5.6%$0.085$0.085$0.0853,000
$0.09+0.005+5.9%$0.065$0.09$0.06566,906
$0.0850.000.0%$0.085$0.085$0.0850
$0.0850.000.0%$0.085$0.085$0.0850
$0.085+0.005+6.3%$0.08$0.09$0.08132,333
$0.08+0.01+14.3%$0.08$0.08$0.088,857
$0.070.000.0%$0.07$0.07$0.070
$0.07-0.01-12.5%$0.07$0.07$0.0712,000
$0.08+0.005+6.7%$0.08$0.08$0.087,000

Splits

2 splits since 2019 · CSE:LOBE · every price before a split is adjusted for it

DayRatioWhat
1-for-6Consolidation
1-for-2Consolidation
Ticker
CSE:LOBE
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
CSE
Currency
CAD

What changed lately

Latest news

All Lobe Sciences Ltd news

Lobe Sciences Ltd on 6ix

Sector
Health care
Industry
Biotechnology
News releases
21 in the last 12 months · 61 in all · newest Oct 20, 2026 · oldest 2023
Decks
6 decks · latest Sep 15, 2026

Where Lobe Sciences Ltd is listed

ListingExchangeCountryCurrency
CSE:LOBE · Home listing · This pageCSECanadaCAD
OTC:LOBEFOTCUnited StatesUSD
Cboe Canada:LOBECboe CanadaCanadaCAD
Frankfurt:LOBEFrankfurtGermanyEUR

Valuation

Price/book 9.5× against a median of 1.8×: 6th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to May 31, 2026 · price Nov 20, 2026

Enterprise value
$12.74M CAD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
9.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P/TSX Composite
0.31

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Lobe Sciences Ltd · CSE:LOBEUS$12.52MUS$8.89Mn/an/an/a9.5×n/a0.0×0.31
Devonian Health Group, Inc. · TSXV:GSDUS$13.09MUS$12.59Mn/a6.0×n/a2.7×−204.1%0.0×0.12
Bolt Biotherapeutics, Inc. · NASDAQ:BOLTUS$12.80MUS$18.89Mn/a7.5×n/a1.5×n/a2.4×0.52
Avai Bio, Inc. · OTC:AVAIUS$12.79MUS$12.67Mn/an/an/an/an/an/a0.28
Neuphoria Therapeutics Inc. · NASDAQ:NEUPUS$12.72M−US$6.03Mn/an/an/a0.5×n/a0.0×0.61
Seres Therapeutics, Inc. · NASDAQ:MCRBUS$12.64MUS$30.89Mn/a14.5×n/a0.6×n/a1.7×1.21
Passage Bio, Inc. · NASDAQ:PASGUS$12.61M−US$7.55Mn/an/an/a252×n/a0.0×1.94
Allarity Therapeutics, Inc. · NASDAQ:ALLRUS$12.56MUS$21.48Mn/a61.4×n/an/an/an/a1.40
Biophytis SA · EURONEXT:ALBPSUS$12.47MUS$19.44Mn/an/an/an/an/an/an/a
MIRA Pharmaceuticals, Inc. · NASDAQ:MIRAUS$12.23MUS$5.26Mn/an/an/a1.8×n/a0.0×1.48
Genflow Biosciences PLC · LSE:GENFUS$12.06MUS$11.23Mn/an/an/a48.5×n/a0.0×n/a
Median of the othersUS$12.63MUS$12.63M11.0×1.8×−204.1%0.0×0.91

Team and board

Officers

OfficerRole
Frederick D. SancilioChairman & Chief Executive Officer
Bob MillerSenior Vice President, Quality and Operations
Mirza RahimaniVice President of Finance
Maghsoud DarianiChief Science Officer
Tracy L. GoekenChief Medical Officer

Board

DirectorRole
Frederick D. SancilioChairman & Chief Executive Officer
Annette GrimaldiDirector
Harry R. JacobsonDirector
Marco Lucio MastrodonatoDirector
Nick KarakochukDirector
Wesley RamjeetDirector

Events

Next results
Dec 28, 2026 (expected)
QuarterResultsShare move
Q2 2023Apr 28, 2023 · Before open−14.3%
Q1 2023Dec 22, 2022 · After close0.0%
Q3 2022Jul 20, 2022 · Before open0.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck29 slidesSep 15, 2026
Investor Presentation (September 2026)Investor deck21 slidesSep 15, 2026
Conference Presentation (September 2026)Conference22 slidesSep 15, 2026
Investor Presentation (July 2026)Investor deck21 slidesJuly 2026
Investor Presentation (June 2026)Investor deck23 slidesJune 2026
Investor Presentation (April 2026)Investor deck21 slidesApril 2026

Open Decks

Financings

RaiseDateIn US dollars
Private placement of common shares
Closed: C$2.16M raised · C$0.085 a share
Use of proceeds: Working capital, general corporate purposes, and advancing the S-100 drug candidate for sickle cell disease, partly via subsidiary Applied Lipid Technologies
Aug 31, 2026
Private placement of common shares
Closed: C$950,000 raised · C$0.065 a share
Use of proceeds: Working capital, general corporate purposes and advancing the S-100 drug candidate for sickle cell disease toward human clinical trials
Apr 20, 2026US$695,461
Private placement of common shares
Closed: C$341,425 raised · C$0.04 a share
Use of proceeds: General corporate purposes, including working capital and ongoing operational needs
Aug 15, 2025US$247,302
Private placement of series A-1 Preferred Stock of subsidiary Cynaptec Pharmaceuticals, Inc.
Closed: US$6M raised · US$1.66 a share
Use of proceeds: Fund preclinical research (including IND enabling studies), Phase 1 and Phase 2a clinical studies for Conjugated Psilocin
Apr 15, 2025
Convertible notes
Terms changed: C$678,450
Apr 5, 2025US$477,244
Convertible note
Closed: US$250,000 raised
Apr 5, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in CAD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0136.2K840.5K00884.8K773.8K00
Cost of revenue01.76K24.0K0
Gross profit0134.4K816.5K0
Research and development641.1K386.2K1.25M418.3K1.37M0
Selling, general and administrative3.54M1.78M2.88M3.69M4.94M2.73M3.27M148.4K51.9K45.8K
Operating income-4.18M-2.12M-3.36M-4.12M-6.32M-2.41M-2.87M-148.4K-51.9K-45.8K
Depreciation and amortization084.7K43.7K10.2K10.2K10.2K371.0K246.2K
EBITDA-4.18M-2.03M-3.32M-4.11M-6.31M-2.40M-2.50M97.8K
Interest expense596.6K186.6K38.6K0043.0K010200
Income before tax-4.86M-4.39M-4.50M-12.3M-23.8M-3.44M-754.4K-148.3K-51.8K-56.0K
Income tax-1.02M
Net income-4.43M-4.42M-4.71M-12.3M-9.66M-3.44M-754.4K-148.3K-51.8K-56.0K
Earnings per share, basic-0.02-0.03-0.06-0.32-0.04-0.02-0.01-0.03-0.01

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents5.85M237.8K140.3K907.5K1.14M172.1K512.8K2.66K29.5K34.5K
Short-term investments1.69M06.28M0
Receivables47.5K9.34K14.9K18.3K1.76M615.4K1.10M71.8K
Inventory017.0K0
Current assets7.59M258.6K319.4K1.04M9.67M1.17M1.99M2.56M30.3K34.9K
Property, plant and equipment571.4K
Total assets7.59M258.6K2.30M1.75M12.1M13.0M6.72M7.44K30.3K34.9K
Accounts payable1.98M784.3K1.92M1.20M745.4K376.8K331.1K115.4K616396
Current liabilities2.43M2.27M2.46M1.30M804.7K776.9K527.6K115.4K6.62K6.40K
Long-term debt273.3K1.11M
Total liabilities2.70M3.37M2.46M1.30M804.7K897.1K527.6K132.1K6.62K6.40K
Shareholders' equity2.36M-3.11M-160.1K445.7K11.3M12.1M6.19M-124.6K23.6K28.5K
Shares outstanding264.1M171.6M79.1M38.5M224.6M143.1M67.8M4.45M4.45M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-1.42M-462.3K-1.72M-2.73M-5.04M-1.22M-2.04M-2.01M-51.9K-44.8K
Capital spending000000-265.1K000
Free cash flow-1.42M-462.3K-1.72M-2.73M-5.04M-1.22M-2.31M-26.9K-51.9K-44.8K
Cash from investing1.07M198.7K-463.8K-10.9M
Cash from financing8.76M563.5K950.0K2.50M4.92M718.7K474.7K18.9M46.9K
Change in cash5.62M101.2K-768.6K-234.3K969.7K-340.7K-1.97M5.97M-5.00K-44.8K

Open Financials

Cap table

Built by 6ix from Lobe Sciences Ltd’s releases · as of Oct 14, 2026

Common shares
359,005,684
Fully diluted
363,005,684

Fully diluted

LineSharesAs of
Common shares359,005,684Aug 31, 2026
Options and RSUs4,000,000Oct 14, 2026

Warrants and options

Lot
RSUs · expiry not stated

Share count over time

CountShares
Aug 31, 2026359,005,684
Aug 31, 2026333,593,922
Aug 20, 2026332,888,040
May 31, 2026308,182,160

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Annette GrimaldiDirector · Since at least Oct 14, 2026
Bob MillerSenior Vice President, Quality and Operations · Since at least Nov 4, 2026
David KideckelUntil Mar 9, 2026 · Past
Frederick D. SancilioChairman & Chief Executive Officer · Since at least Oct 20, 2026
Harry R. JacobsonDirector · Since at least Jun 9, 2026
Maghsoud DarianiChief Science Officer · Since at least Nov 5, 2026
Marco MastrodonatoDirector · Since at least Sep 9, 2025
Mirza RahimaniVice President of Finance · Since at least Mar 9, 2026
Nick KarakochukDirector · Since at least Jan 13, 2026
Tracy L. GoekenChief Medical Officer · Since Oct 20, 2026
All 12 people
PersonSeat
Wesley RamjeetDirector · Since at least Jun 9, 2026
Yong YaoChief Financial Officer · Jun 3, 2025 – Nov 4, 2026 · Past

Open People

Log in to ask 6ix AI your own questions about Lobe Sciences Ltd.